Asthma is a heterogeneous chronic inflammatory airway disease that affects approximately 300 million people worldwide, with about 5–10% of all asthmatics suffering from severe or uncontrolled asthma.

This narrative review analyzes the impact of biological agents that are currently approved and under investigation in order to aid the selection by clinicians of the appropriate biological drug for the management of each severe asthma phenotype.

There is medical need for head-to-head comparison studies of biologics as well as to identify biomarkers for asthma diagnosis, prognosis, and response to treatment.

It is important to identify prognostic and therapeutic biomarkers that characterize specific phenotypes of severe asthma, as this should allow therapeutic strategies that are specifically tailored to individual patients to be devised.

Identifying novel biomarkers could facilitate the development of therapeutic strategies that are precisely tailored to each patient’s requirements.